Gain Therapeutics Completes Target Enrollment in Phase 1b GT-02287 Study for Parkinson’s with or without GBA1 Mutation

ReutersJun 30, 2025 8:16 PM

June 30 (Reuters) - Gain Therapeutics Inc GANX.O:

GAIN THERAPEUTICS ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 1B CLINICAL STUDY EVALUATING GT-02287 IN PEOPLE WITH PARKINSON’S DISEASE WITH OR WITHOUT A GBA1 MUTATION
GAIN THERAPEUTICS INC - BIOMARKER ANALYSIS EXPECTED IN 4Q 2025, EARLIER THAN PLANNED
GAIN THERAPEUTICS INC - EXTENDS SCREENING FOR PHASE 1B TRIAL THROUGH JULY 31, 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

IONQ First-Quarter Earnings Beat Expectations, Shares Fall After Hours; Is IONQ Still Worth Investing?

TradingKey - IONQ’s latest earnings beat expectations, but shares fell after-hours as the market had previously overextended performance expectations; the medium-to-long-term outlook remains bullish.

Trump Family Mining Firm American Bitcoin Losses Widen, Why the Market Is Still Buying?

American Bitcoin reported widening losses for Q1 2026, yet its stock price remained resilient amid rising Bitcoin prices, with the potential for further gains in the near term.

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

TradingKey - Dell Technologies (DELL) results are due late this month and the setup is unusual. The company is a key provider of AI infrastructure, yet its valuation multiple has expanded much more modestly than peers in the semiconductor, networking, memory, and storage sectors. As we head into ear

SK Hynix Shares Hit New High Above 1.6 Million Won; Where Does the Upward Momentum Come From?

TradingKey - During the Asian session on May 6, South Korean memory chip giant SK Hynix surged more than 10% intraday, with its closing price exceeding 1.6 million KRW, marking a record high for the second consecutive trading day. The company's market capitalization surpassed 1,100 trillion KRW, with its cumulative year-to-date gain reaching over 146%.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools